About Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
PFE - Pfizer| Previous Close | $37.92 | Open | $37.04 |
| Volume | 34.96M | Market Cap | 210.717B |
| Yield | 3.96 % | Last Dividend | $1.50 |
| Highly anticipated COVID-19 vaccine data... | 5:09 PM |
| Pfizer???s effectiveness data for its highly anticipated COVID-19 vaccine is still not available, and unlikely to come by Election Day. | |
| FXNEWS24 |Pfizer CEO All but Rules Out C... | 4:10 PM |
| Pfizer CEO All but Rules Out Covid-19 Vaccine Before Election Day | UK Stocks, Forex, Commodities, Crypto, Live Market News- Daily Forex News | |
| Pfizer C.E.O. All but Rules Out Vaccine ... | 2:54 PM |
| Pfizer???s C.E.O. said on Tuesday that much-anticipated results from its vaccine trial would not be coming this month, after all. | |
| FXNEWS24 |Coronavirus vaccine data from ... | 1:40 PM |
| Coronavirus vaccine data from Pfizer unlikely to come before U.S. election | UK Stocks, Forex, Commodities, Crypto, Live Market News- Daily Forex News | |
| Pfizer's COVID-19 Vaccine Phase 3 Trial ... | 11:44 AM |
| Pfizer has made significant progress as it nears 42,000 enrollments to participate in its last stage of the Pfizer???s COVID-19 vaccine trial. | |
| Pfizer says release of Covid vaccine dat... | 11:39 AM |
| PFIZER-RESULTS/ (UPDATE 6, PIX):UPDATE 6-Pfizer says no COVID-19 vaccine data yet, could be week or more before it reports | |
| Pfizer Says No COVID-19 Vaccine Data Yet... | 11:27 AM |
| Drugmaker Pfizer Inc said on Tuesday it does not yet have data from the latestage trial of the COVID19 vaccine it is developing with Germany's BioNTec... | |
| Pfizer???s Covid-19 vaccine doesn???t ad... | 11:00 AM |
| Navin Jacob - UBS Pharmaceuticals Analyst joins Yahoo Finance???s On The Move panel to deep dive into the latest pharmaceutical earnings reports. | |
| Pfizer Reports Lower Profits, Not Yet Re... | 10:51 AM |
|
Pfizer reported a 71% drop in profit to $2.2 billion as Covid-19 dented demand for some medicines from patients whose regular health care patterns ... |
|
| Pfizer Says Covid-19 Vaccine Late-Stage ... | 10:38 AM |
| The Covid-19 pandemic weighed down sales for some drugs in the latest quarter as the company???s candidate vaccine for the virus that has caused the p... | |
| Crucial Covid vaccine data expected from... | 9:56 AM |
| Data is a real-time snapshot *Data is delayed at least 15 minutes. Global Business and Financial News, Stock Quotes, and Market Data and Analysis. | |
| Pfizer Stock Is Lower Because the Covid-... | 9:05 AM |
| Drug giant Pfizer is getting close to knowing whether its Covid-19 vaccine is safe and effective. But meanwhile third-quarter earnings show the drug g... | |
| No news on Pfizer???s Covid-19 vaccine i... | 8:46 AM |
| Pfizer revealed that researchers have not yet conducted an analysis of the efficacy of the vaccine it is developing against Covid-19. The announcement... | |
| Psychedelic Drugs Market (COVID-19 Impac... | 8:42 AM |
| This Psychedelic Drugs Market research report makes available state-of-the-art information about the entire market along with the holistic view of the... | |
| Pfizer not ready to release Covid-19 vac... | 8:25 AM |
| FDA inspections are not required for drug makers seeking emergency use authorization of a therapy or vaccine for Covid-19. | |
| Pfizer not ready to release coronavirus ... | 8:25 AM |
| Pfizer hopes to be the first US drugmaker to unveil successful data from a late-stage Covid vaccine trial, ahead of rival Moderna Inc. Pfizer and BioN... | |
| Drug Transport Technology Market Growing... | 8:22 AM |
| The movement of drug molecules after their absorption is essential to get their pharmacological action. Transportation is a process by which drug mole... | |
| Nasal Delivery Devices Market to highest... | 7:20 AM |
| The Global Nasal Delivery Devices Market is expected to reach US$ 95,676.62 million by 2027 from US$ 58,502.18 million in 2019. The market is estimate... | |
| Pfizer Tops 3Q Earnings Views, Makes Pro... | 6:51 AM |
| Drugmaker Pfizer saw its third-quarter profit plunge 71%, mainly due to an $8.1 billion gain a year earlier from selling its consumer health care busi... | |
| US Open ??? Justice Barrett, Earnings (H... | 6:51 AM |
| European stocks weakened, while US stocks rallied, fed by investor optimism that the presidential election would deliver a ???blue wave??? and provide... | |
| Pfizer reports lower earnings as Covid-1... | 6:42 AM |
| ??? | |
| Pfizer (PFE) posts mixed results in Q3 | 6:42 AM |
| Pfizer Inc (NYSE: PFE) reported third-quarter 2020 financial results before the opening bell on Tuesday. The pharmaceutical giant reported a 4% declin... | |
| Pharmaceutical Drug Delivery Market Top ... | 6:36 AM |
| Summary of the Pharmaceutical Drug Delivery Market Report Due to the various economic, technological, research & development and geographical aspects,... | |
| Osteoporosis Drugs Market Top Key Player... | 6:33 AM |
| Summary of the Osteoporosis Drugs Market Report Due to the various economic, technological, research & development and geographical aspects, the Osteo... | |
| Pfizer not yet ready to release COVID-19... | 6:26 AM |
| REUTERS: Drugmaker Pfizer Inc said on Tuesday it was not yet ready to release data from the late-stage trial of the COVID-19 vaccine candidate it is d... | |
| Pfizer tops earnings expectations | 6:19 AM |
| Pfizer is reporting a third-quarter profit of $2.19 billion | |
| Pfizer says planning Phase 2/3 study of ... | 6:11 AM |
| But the firm says they still plan to apply for emergency use of its coronavirus vaccine in late November, if the data is positive However, the data mo... | |
| Pfizer Tops Q3 Earnings Forecast, Narrow... | 6:04 AM |
| Pfizer posted better-than-expected third quarter earnings Tuesday, and narrowed its full-year profit forecast, while noting it still plans to apply fo... | |
| Buy rating | 10/23/20 |
| Truist Securities initiates coverage with Buy rating and announces Price Target of $42.00 | |
| Hold rating | 10/12/20 |
| Atlantic Equities downgrades from Overweight to Neutral rating and lowers Price Target from $44.00 to $39.00 | |
| Hold rating | 09/29/20 |
| Berenberg initiates coverage with Hold rating and announces Price Target of $38.00 | |
| Hold rating | 07/30/20 |
| Morgan Stanley maintains Equal-Weight rating and raises Price Target from $36.00 to $42.00 | |
| Date | Today (BMO) | Est. (EPS/Rev.) | $0.71/ 12.33B |
| Actual (EPS/Rev.) | $0.72/ $12.13 B | EPS (TTM) | 2.84 |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Service Name | Trader | % Success | |
|---|---|---|---|
| M.I.B | Jay | 97.00 % | Follow |
| Swingtrades | R. belegger | 83.00 % | Follow |
| Free Biotech Holdings | Scientia Equity Research | 83.00 % | Follow |
| Tech Trades | Tech Trades | 82.00 % | Follow |
| Big Data Zhou | Zhou Academy | 82.00 % | Subscribe |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
